Correction to: Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Detalles Bibliográficos
Autores principales: Glassberg, Marilyn K., Nathan, Steven D., Lin, Chin-Yu, Morgenthien, Elizabeth A., Stauffer, John L., Chou, Willis, Noble, Paul W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822818/
https://www.ncbi.nlm.nih.gov/pubmed/31502216
http://dx.doi.org/10.1007/s12325-019-01082-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822818/
https://www.ncbi.nlm.nih.gov/pubmed/31502216
http://dx.doi.org/10.1007/s12325-019-01082-6

Ejemplares similares